Polymorphisms in arachidonic acid metabolism-related genes and the risk and prognosis of colorectal cancer

Familial Cancer

Volumn 12, Issue 4, 2013, Pages 755-765

  Li, Shuying ^a   Zhao, Xiaojuan ^a   Wu, Zhiwei ^a   Li, Ye ^a   Zhu, Lin ^a   Cui, Binbin ^a   Dong, Xinshu ^a   Tian, Suli ^a   Hu, Fulan ^a   Zhao, Yashuang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

12 LOX; Colorectal cancer; COX 2; Polymorphism; Prognosis

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; CISPLATIN; CYCLOOXYGENASE 2; FLUOROURACIL; NAVELBINE; PHOSPHOLIPASE A2;

ADULT; AGED; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CASE CONTROL STUDY; CHINA; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ENZYME POLYMORPHISM; FEMALE; FOLLOW UP; FOOD INTAKE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION;

ANTIGENS, HUMAN PLATELET; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONIC ACID; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; FOLLOW-UP STUDIES; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888204768     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-013-9659-2     Document Type: Article

References (53)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29. doi: 10.3322/caac.20138
2. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, Guizard AV, Molinie F, Danzon A, Bara S, Bouvier AM, Tretarre B, Binder-Foucard F, Colonna M, Daubisse L, Hedelin G, Launoy G, Le Stang N, Maynadie M, Monnereau A, Troussard X, Faivre J, Collignon A, Janoray I, Arveux P, Buemi A, Raverdy N, Schvartz C, Bovet M, Cherie-Challine L, Esteve J, Remontet L, Velten M (2008) Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 56(3):159-175. doi: 10.1016/j.respe.2008.03.117
3. Yiu HY, Whittemore AS, Shibata A (2004) Increasing colorectal cancer incidence rates in Japan. Int J Cancer 109(5):777-781. doi: 10.1002/ijc.20030
4. http://globocan.iarc.fr/factsheets/cancers/colorectal.asp
5. Sun X, Liu W, Wu S, Han H, Lin Y, Dai X (2005) The morbidity and mortality trend and prediction of lung cancer in residents of Nangang District of Harbin in China during the past 10 years. Zhongguo Fei Ai Za Zhi 8(6):514-517. doi: 10.3779/j.issn.1009-3419.2005.06.06
6. Goel A, Boland CR (2010) Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol 26(1):47-52. doi: 10.1097/MOG.0b013e328332b850
7. Dong J, Dai J, Zhang M, Hu Z, Shen H (2010) Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol 25(6):1042-1050. doi: 10.1111/j.1440-1746.2010.06293.x
8. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (2008) Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 14(23):7884-7895. doi: 10.1158/1078-0432.CCR-07-5165
9. Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, Karakitsos P (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48(6):563-569. doi: 10.1002/mc.20495
10. Castro FA, Forsti A, Buch S, Kalthoff H, Krauss C, Bauer M, Egberts J, Schniewind B, Broering DC, Schreiber S, Schmitt M, Hampe J, Hemminki K, Schafmayer C (2011) TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 47(8):1203-1210. doi: 10.1016/j.ejca.2010.12.011
11. Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S (2003) Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem 253(1-2):141-149
12. Dong M, Guda K, Nambiar PR, Rezaie A, Belinsky GS, Lambeau G, Giardina C, Rosenberg DW (2003) Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 24(2):307-315
13. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM (1995) The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81(6):957-966. doi: 10.1016/0092-8674(95)90015-2
14. Smith WL, Langenbach R (2001) Why there are two cyclooxygenase isozymes. J Clin Invest 107(12):1491-1495. doi: 10.1172/JCI13271
15. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356(21):2131-2142. doi: 10.1056/NEJMoa067208
16. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM (2004) HER2 and COX2 expression in human prostate cancer. Eur J Cancer 40(1):50-55. doi: 10.1016/j.ejca.2003.08.010
17. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM (2004) Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45(1):47-54. doi: 10.1111/j.1365-2559.2004.01898.x
18. Kamitani H, Geller M, Eling T (1999) The possible involvement of 15-lipoxygenase/leukocyte type 12-lipoxygenase in colorectal carcinogenesis. Adv Exp Med Biol 469:593-598
19. Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ, Honn KV (1998) Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 58(18):4047-4051
20. Natarajan R, Esworthy R, Bai W, Gu JL, Wilczynski S, Nadler J (1997) Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. J Clin Endocrinol Metab 82(6):1790-1798
21. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294(5548):1871-1875. doi: 10.1126/science.294.5548.1871
22. Bennett A, Tacca MD, Stamford IF, Zebro T (1977) Prostaglandins from tumours of human large bowel. Br J Cancer 35(6):881-884
23. Pugh S, Thomas GA (1994) Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 35(5):675-678
24. Nie D, Tang K, Diglio C, Honn KV (2000) Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 95(7):2304-2311
25. Tang DG, Chen YQ, Honn KV (1996) Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 93(11):5241-5246
26. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, Zhang B, Zhao D, Yang M, Yu D, Lin D (2007) Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28(6):1197-1201. doi: 10.1093/carcin/bgl242
27. Hoff JH, te Morsche RH, Roelofs HM, van der Logt EM, Nagengast FM, Peters WH (2009) COX-2 polymorphisms -765G→C and -1195A→G and colorectal cancer risk. World J Gastroenterol 15(36):4561-4565
28. Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, Li L (2009) No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol 15(18):2240-2244
29. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ (2006) Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 119(2):297-303. doi: 10.1002/ijc.21858
30. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC (2004) Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 25(12):2467-2472. doi: 10.1093/carcin/bgh260
31. Prasad VV, Padma K (2012) Non-synonymous polymorphism (Gln261Arg) of 12-lipoxygenase in colorectal and thyroid cancers. Fam Cancer. doi: 10.1007/s10689-012-9559-x
32. Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L (2010) Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res 16(8):2383-2390. doi: 10.1158/1078-0432.CCR-09-2793
33. Gao X, Porter AT, Honn KV (1997) Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv Exp Med Biol 407:41-53
34. Potter JD, McMichael AJ (1986) Diet and cancer of the colon and rectum: a case-control study. J Natl Cancer Inst 76(4):557-569
35. Steinmetz KA, Potter JD (1993) Food-group consumption and colon cancer in the Adelaide case-control study. II. Meat, poultry, seafood, dairy foods and eggs. Int J Cancer 53(5):720-727
36. Potter JD, Slattery ML, Bostick RM, Gapstur SM (1993) Colon cancer: a review of the epidemiology. Epidemiol Rev 15(2):499-545
37. van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, Jenab M, Boshuizen HC, Ros MM, Casagrande C, Tjonneland A, Olsen A, Overvad K, Thorlacius-Ussing O, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Kaaks R, Linseisen J, Boeing H, Nothlings U, Trichopoulou A, Trichopoulos D, Misirli G, Palli D, Sieri S, Panico S, Tumino R, Vineis P, Peeters PH, van Gils CH, Ocke MC, Lund E, Engeset D, Skeie G, Suarez LR, Gonzalez CA, Sanchez MJ, Dorronsoro M, Navarro C, Barricarte A, Berglund G, Manjer J, Hallmans G, Palmqvist R, Bingham SA, Khaw KT, Key TJ, Allen NE, Boffetta P, Slimani N, Rinaldi S, Gallo V, Norat T, Riboli E (2009) Fruit, vegetables, and colorectal cancer risk: the European prospective investigation into cancer and nutrition. Am J Clin Nutr 89(5):1441-1452. doi: 10.3945/ajcn.2008.27120
38. Wei YS, Lu JC, Wang L, Lan P, Zhao HJ, Pan ZZ, Huang J, Wang JP (2009) Risk factors for sporadic colorectal cancer in southern Chinese. World J Gastroenterol 15(20):2526-2530
39. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ (2008) MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75(4):380-385. doi: 10.1159/000108407
40. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, Overvad K, Tjonneland A (2008) Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 639(1-2):89-100. doi: 10.1016/j.mrfmmm.2007.11.004
41. Gong Z, Hebert JR, Bostick RM, Deng Z, Hurley TG, Dixon DA, Nitcheva D, Xie D (2007) Common polymorphisms in 5-lipoxygenase and 12-lipoxygenase genes and the risk of incident, sporadic colorectal adenoma. Cancer 109(5):849-857. doi: 10.1002/cncr.22469
42. Romano M, Claria J (2003) Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 17(14):1986-1995. doi: 10.1096/fj.03-0053rev
43. Dayer P, Courvoisier F, Kupfer A, Balant-Gorgia A, Balant L, Fabre J (1983) Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation. Schweiz Med Wochenschr 113(8):295-297
44. Hoeft B, Linseisen J, Beckmann L, Muller-Decker K, Canzian F, Husing A, Kaaks R, Vogel U, Jakobsen MU, Overvad K, Hansen RD, Knuppel S, Boeing H, Trichopoulou A, Koumantaki Y, Trichopoulos D, Berrino F, Palli D, Panico S, Tumino R, Bueno-de-Mesquita HB, van Duijnhoven FJ, van Gils CH, Peeters PH, Dumeaux V, Lund E, Huerta Castano JM, Munoz X, Rodriguez L, Barricarte A, Manjer J, Jirstrom K, Van Guelpen B, Hallmans G, Spencer EA, Crowe FL, Khaw KT, Wareham N, Morois S, Boutron-Ruault MC, Clavel-Chapelon F, Chajes V, Jenab M, Boffetta P, Vineis P, Mouw T, Norat T, Riboli E, Nieters A (2010) Polymorphisms in fatty-acid-metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis 31(3):466-472. doi: 10.1093/carcin/bgp325
45. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(10):883-890. doi: 10.1056/NEJMoa021633
46. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369(9573):1603-1613. doi: 10.1016/S0140-6736(07)60747-8
47. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146(5):365-375. doi: 10.7326/0003-4819-146-5-200703060-00009
48. Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM (2003) Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 88(6):803-807. doi: 10.1038/sj.bjc.6600829
49. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J (2005) PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14(3):616-619. doi: 10.1158/1055-9965.EPI-04-0510
50. Siezen CL, Tijhuis MJ, Kram NR, van Soest EM, de Jong DJ, Fodde R, van Kranen HJ, Kampman E (2006) Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics 16(1):43-50
51. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15(6):1126-1131. doi: 10.1158/1055-9965.EPI-06-0042
52. Ali IU, Luke BT, Dean M, Greenwald P (2005) Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer 93(8):953-959. doi: 10.1038/sj.bjc.6602806
53. Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, de Cotret AR, Player J, Sandler RS (2006) COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control 17(3):257-266. doi: 10.1007/s10552-005-0417-0